Farid Ahmed PhD

Leukemia and stem cell researcher. Trying to understand how drug resistance develops in leukemia. Love mountain biking and coffee.

[Farid Ahmed PhD @FaridPhD]

FDA approves rusfertide, the first hepcidin mimetic therapy for polycythemia vera. https://t.co/STL6KmyifH

[Abdel-Wahab Lab @AbdelWahablab]

Excited to share our paper out today in @CellPressNews discovering RNA mis-splicing derived neoantigens & their cognate T cell receptors (TCRs) as well as characterization of endogenous neoantigen T cells in leukemia patients.

https://t.co/hVucfdL0oZ

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

Excited to see this paper out in @BloodPortfolio ; check it out in case you are curious to know more about the process of the upcoming #CAM #Hematopathology #WHOClassification https://t.co/vUCshkBZQU @KMirza @doctorpemm @AkEisfeld @Daver_Leukemia

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

https://t.co/auhUikXuRW

[Farid Ahmed PhD @FaridPhD]

@MicrobiomDigest S and GSH are same images

[Farid Ahmed PhD @FaridPhD]

@MicrobiomDigest m & g

[Blood Neoplasia @Bloodneoplasia]

Combined loss of the 7q genes CUX1 and EZH2 impairs the DNA damage response, driving hematopoietic clonal expansion and drug resistance. https://t.co/8pUbXL3DTs #myeloidneoplasia

[Talha Badar @TalhaBadarMD]

#ASCO25 Should we treat older adult with #TP53m #AML? 👇🏽 Have a look at our poster today. #COMMAND_consortium @Dr_RoryShallis @Dr_AmerZeidan @Anand_88_Patel @yasminabaza1 @AlexColtoff @ChenyuLinMD et al.

[Farid Ahmed PhD @FaridPhD]

@mayadh_220 @DkBasmah @Ahdab_Als Congratulations Mayadh and your amazingly steadfast supervisors @DkBasmah and @Ahdab_Als for getting this work done. I wish you all the best in your scientific progress.

[Julia Maxson @juliamaxson]

A new paper from @LucieDarmusey out this week in Blood Advances! Dr. Darmusey investigated how mutations in ASXL1--often associated with dysplasia--also drive myeloproliferative neoplasms, which are characterized by overproduction of mature cells.

https://t.co/1dPUKyxY27

[Farid Ahmed PhD @FaridPhD]

@EHA_Hematology 4

[مركز الملك فهد للبحوث الطبية @KFMRC_KAU]

The 1st KFMRC Conference – Medical Research Across Specialties!
A key event for researchers, clinicians, and students to connect, share insights, and drive innovation.
April 20 – 24, 2025King Fahd Medical Research Center
Join us Now
#KFMRC_Conference

[Farid Ahmed PhD @FaridPhD]

Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1RAs https://t.co/3LhgGaZ7sj

[Alejo Rodriguez-Fraticelli @AlejoFraticelli]

🔥New Fraticelli lab publication🔥

“Pre-existing stem cell heterogeneity dictates clonal responses to the acquisition of leukemia driver mutations”

Two new figures compared to the pre-print, with more in vivo and sequential mutagenesis data.

https://t.co/2MByy2tcO0

[OncLive.com @OncLive]

@DrHKantarjian of @MDAndersonNews presents the Phase I/II SAVE trial results, showcasing the promising efficacy and safety of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in relapsed/refractory AML.

https://t.co/Q9TL6tytHM

[ISEH @ISEHSociety]

This month's #PreprintWatch covers some exciting new results on the impact of microenvironment on hematopoietic progenitors and novel approaches to long-standing questions like self-renewal and stem cell activity! Read now on https://t.co/2NCQisaloN

[Talha Badar @TalhaBadarMD]

Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study https://t.co/eAezSJ3kMv

#AML #leusm

[مؤسسة الملك عبدالعزيز ورجاله للموهبة والإبداع @mawhiba]

🎉🏆🎉

مبارك للمبدعين الفائزين بالمركز الخامس من الجوائز الكبرى في مسار صحة الإنسان في #إبداع_2025

[Ani Deshpande @anideshpandelab]

Our institute is excited to host The Myeloid Precursor this Thursday, a fun mini symposium on AML with great talks, a panel discussion on AML, and a poster session. If you are in San Diego this Thursday and interested, please register here. https://t.co/8MFjjLBfTM

[Munich Leukemia Laboratory @leukaemielabor]

📄Identification of a new germline mutation: JAK2 F556V, a gain-of-function mutation 📈JAK-STAT5 signaling. This study reveals its role in familial thrombocythemia, highlighting the hereditary aspect of JAK2 mutations & their impact on platelet counts.
https://t.co/NZ6sQKeZq9